Add BrightSurf on Google Email

Nourishing T cells to fight cancer

Researchers at the University of Pittsburgh have developed a new way to grow T cells that can live longer and better destroy cancer cells in mice. By adding a compound called dichloroacetate to growth media, they created T cells less reliant on glucose and more efficient at using other energy sources.

SourceUniversity of Pittsburgh·JournalCell Metabolism·DateJan 28, 2025

Anti-correlation between KLRG1 and PD-1 in tumor CD8 T cells

A new study published in Oncotarget discovered an anti-correlation between PD-1 and KLRG1 expression in human tumor infiltrating CD8 T cells. This finding suggests the potential for combination therapy to enhance cancer treatment by targeting both markers simultaneously, which could lead to more significant and long-lasting benefits.

SourceImpact Journals LLC·JournalOncotarget·TypeNews article·DateJan 21, 2025

Researchers shed light on how to predict which skin cancer patients are most likely to respond to immunotherapy

A new study has identified macrophage activity as a key predictor of which skin cancer patients are most likely to respond to immunotherapy. The findings aim to improve personalized medicine for cancer patients and enable clinicians to select effective treatments, reducing side effects and costs.

SourceUniversity of Bath·JournalJCO Oncology Advances·TypeExperimental study·DateJan 8, 2025

Cancer-preventing topical immunotherapy trains the immune system to fight precancers

A new study by Mass General Brigham researchers reveals that a novel immunotherapy can eliminate precancerous spots and prevent skin cancer through the activation of specific immune cells. The therapy successfully cleared over 95% of facial lesions and showed long-term efficacy, with benefits lasting up to five years after treatment.

SourceMass General Brigham·JournalJournal of Clinical Investigation·TypeRandomized controlled/clinical trial·DateJan 2, 2025

Your immune cells are what they eat

Researchers at Salk Institute establish a novel framework for the relationship between nutrition and cell identity. They found that a nutritional switch from acetate to citrate plays a key role in determining T cell fates, shifting them from active effector cells to exhausted cells.

SourceSalk Institute·JournalScience·DateDec 12, 2024

Innovative immunotherapy shows promise in early clinical trial for breast cancer

A groundbreaking phase one clinical trial explores a novel cell-based immunotherapy for breast cancer, demonstrating significant shrinkage of tumors and minimal side effects. The treatment leverages dendritic cells to trigger an organized immune system attack on cancer, offering hope for replacing or reducing the need for chemotherapy.

SourceKent State University·JournalJAMA Oncology·TypeRandomized controlled/clinical trial·DateDec 5, 2024

Probiotic delivers anticancer drug to the gut

Researchers at WashU Medicine engineered a probiotic that delivers immunotherapy directly to the gut, shrinking tumors in mice. The probiotic uses a yeast-based system to produce immune checkpoint inhibitors, potentially treating hard-to-reach cancers.

SourceWashU Medicine·JournalCell Chemical Biology·TypeExperimental study·DateNov 20, 2024

POSTECH team pioneers new cancer therapy strategy: targeting GLUT3 in regulatory T cells to supercharge anti-tumor immunity

Researchers at POSTECH have identified GLUT3 as essential for the suppressive function of regulatory T cells in tumor microenvironments, which can be targeted for cancer immunotherapy. The team's findings highlight the critical role of GLUT3 in regulating protein modifications that sustain immune suppression within tumors.

SourcePohang University of Science & Technology (POSTECH)·JournalCellular and Molecular Immunology·DateNov 12, 2024

Combination approach shows promise for treating rare, aggressive cancers

Researchers at UCLA Health Jonsson Comprehensive Cancer Center have shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with advanced small cell bladder cancer and small cell/neuroendocrine prostate cancer. The study found that the combination treatment resul...

Immunotherapy drug pembrolizumab improves outcomes for patients with soft tissue sarcoma

A new clinical trial found that the addition of immunotherapy drug pembrolizumab to standard treatment improved disease-free survival rates for patients with stage 3 soft tissue sarcoma. The study showed that pembrolizumab reduced recurrence or death for patients by 15 percentage points compared to standard treatment.

SourceUniversity of Pittsburgh·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateNov 12, 2024

Combining the VIGex gene expression signature with liquid biopsy may improve response prediction to immunotherapy

Researchers have found that combining the VIGex gene expression signature with liquid biopsy analysis improves response prediction to immunotherapy in patients with advanced solid tumors. The study analyzed tumor samples and circulating tumor DNA (ctDNA) by liquid biopsy, showing that the VIGex-Hot subgroup was associated with higher o...

SourceVall d'Hebron Institute of Oncology·JournalJCO Precision Oncology·DateNov 7, 2024

Novel immunotherapy combo shows promise in melanoma

A phase 2 clinical trial found that the combination of vidutolimod and nivolumab led to tumor control in 55% of patients, with higher levels of immune-related proteins detected in responders. The study also uncovered unique signatures of TLR9 activation and a link between gut microbiome and response to therapy.

SourceUniversity of Pittsburgh·JournalCancer Cell·TypeRandomized controlled/clinical trial·DateNov 1, 2024